Literature DB >> 31483064

Changes in whole body pain intensity and widespreadness during urologic chronic pelvic pain syndrome flares-Findings from one site of the MAPP study.

Tianlin Xu1,2, H Henry Lai3,4, Ratna Pakpahan2, Joel Vetter3, Gerald L Andriole3, Catherine Bradley5, Bruce D Naliboff6, Graham A Colditz2, Siobhan Sutcliffe2.   

Abstract

OBJECTIVE: To investigate changes in whole body pain during urologic chronic pelvic pain syndrome (UCPPS) flares.
MATERIALS AND METHODS: UCPPS participants at one site of the multidisciplinary approach to the study of chronic pelvic pain research network reported their daily flare status and pain levels in 7 pelvic/genital and 42 extrapelvic body areas (scale = 0-10) for 10 days at baseline and during their first flare. Linear mixed models and conditional logistic regression were used to investigate symptom changes during flares. Analyses were stratified by chronic overlapping pain condition (COPC) status.
RESULTS: Fifty-five out of 60 participants completed the study, 27 of whom provided information on both nonflare (n = 281) and flare (n = 208) days. Pelvic/genital pain intensity (mean change = 3.20 of 10) and widespreadness (mean = 1.48) increased significantly during flares for all participants (all P interaction > .1), whereas extrapelvic pain intensity increased significantly only among participants with COPCs (mean = 2.09; P interaction < .0001). Pelvic/genital and extrapelvic pain also varied on nonflare days but symptom fluctuations were generally ≤1 point (80.0%-100% of participants). Increases of ≥2 points in pelvic/genital pain intensity (odds ratio (OR) = 22.0, 95% confidence interval (CI) = 4.0-118.6) and ≥1 point in urination-related pain (OR = 9.10, 95% CI = 1.74-47.7) were independently associated with flare onset for all participants.
CONCLUSION: Our observations of extrapelvic pain increases during flares for patients with COPCs and our independent associations between pelvic/genital/urination-related pain intensity and flare onset may provide insight into mechanisms underlying flare development (eg, common biologic pathways between UCPPS phenotypes and flares), flare management (eg, local vs systemic therapies by COPC status), and patient flare definitions.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  chronic prostatitis; flares; interstitial cystitis; longitudinal study; symptom exacerbations

Mesh:

Year:  2019        PMID: 31483064      PMCID: PMC9188843          DOI: 10.1002/nau.24150

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.367


  22 in total

Review 1.  Advances in the assessment of fibromyalgia.

Authors:  David A Williams; Stephen Schilling
Journal:  Rheum Dis Clin North Am       Date:  2009-05       Impact factor: 2.670

2.  Gabapentenoids in pain management in urological chronic pelvic pain syndrome: Gabapentin or pregabalin?

Authors:  Mayank Mohan Agarwal; Mudelin Elsi Sy
Journal:  Neurourol Urodyn       Date:  2017-02-10       Impact factor: 2.696

3.  Characterization of Whole Body Pain in Urological Chronic Pelvic Pain Syndrome at Baseline: A MAPP Research Network Study.

Authors:  H Henry Lai; Thomas Jemielita; Siobhan Sutcliffe; Catherine S Bradley; Bruce Naliboff; David A Williams; Robert W Gereau; Karl Kreder; J Quentin Clemens; Larissa V Rodriguez; John N Krieger; John T Farrar; Nancy Robinson; J Richard Landis
Journal:  J Urol       Date:  2017-03-31       Impact factor: 7.450

4.  A prospective study of symptoms and quality of life in men with chronic prostatitis/chronic pelvic pain syndrome: the National Institutes of Health Chronic Prostatitis Cohort study.

Authors:  Kathleen Joy Propert; Mary McNaughton-Collins; Benjamin E Leiby; Michael P O'Leary; John W Kusek; Mark S Litwin
Journal:  J Urol       Date:  2006-02       Impact factor: 7.450

5.  Effect of amitriptyline on symptoms in treatment naïve patients with interstitial cystitis/painful bladder syndrome.

Authors:  Harris E Foster; Philip M Hanno; J Curtis Nickel; Christopher K Payne; Robert D Mayer; David A Burks; Claire C Yang; Toby C Chai; Karl J Kreder; Kenneth M Peters; Emily S Lukacz; Mary P FitzGerald; Liyi Cen; J Richard Landis; Kathleen J Propert; Wei Yang; John W Kusek; Leroy M Nyberg
Journal:  J Urol       Date:  2010-03-29       Impact factor: 7.450

6.  A longitudinal analysis of urological chronic pelvic pain syndrome flares in the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network.

Authors:  Siobhan Sutcliffe; Robert Gallop; Hing Hung Henry Lai; Gerald L Andriole; Catherine S Bradley; Gisela Chelimsky; Thomas Chelimsky; James Quentin Clemens; Graham A Colditz; Bradley Erickson; James W Griffith; Jayoung Kim; John N Krieger; Jennifer Labus; Bruce D Naliboff; Larissa V Rodriguez; Suzette E Sutherland; Bayley J Taple; John Richard Landis
Journal:  BJU Int       Date:  2019-05-29       Impact factor: 5.588

7.  A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis.

Authors:  Arndt van Ophoven; Sasa Pokupic; Achim Heinecke; Lothar Hertle
Journal:  J Urol       Date:  2004-08       Impact factor: 7.450

8.  Symptom Variability and Early Symptom Regression in the MAPP Study: A Prospective Study of Urological Chronic Pelvic Pain Syndrome.

Authors:  Alisa J Stephens-Shields; J Quentin Clemens; Thomas Jemielita; John Farrar; Siobhan Sutcliffe; Xiaoling Hou; J Richard Landis
Journal:  J Urol       Date:  2016-04-27       Impact factor: 7.450

9.  Changes in symptoms during urologic chronic pelvic pain syndrome symptom flares: findings from one site of the MAPP Research Network.

Authors:  Siobhan Sutcliffe; Graham A Colditz; Ratna Pakpahan; Catherine S Bradley; Melody S Goodman; Gerald L Andriole; H Henry Lai
Journal:  Neurourol Urodyn       Date:  2013-11-23       Impact factor: 2.696

10.  The MAPP research network: a novel study of urologic chronic pelvic pain syndromes.

Authors:  J Quentin Clemens; Chris Mullins; John W Kusek; Ziya Kirkali; Emeran A Mayer; Larissa V Rodríguez; David J Klumpp; Anthony J Schaeffer; Karl J Kreder; Dedra Buchwald; Gerald L Andriole; M Scott Lucia; J Richard Landis; Daniel J Clauw
Journal:  BMC Urol       Date:  2014-08-01       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.